Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

llion (US$2.5 million).

-- Earnings per American depositary share ("ADS") for the fourth quarter

2007 were RMB0.82 (US$0.11), compared to RMB0.50 for the fourth quarter

2006.

Fiscal Year 2007 Financial Highlights:

Compared to fiscal year 2006 results,

-- Total net revenues increased 41.0% to RMB180.2 million (US$24.7

million).

-- Net revenue from EPIAO increased 22.6% to RMB121.2 million (US$16.6

million).

-- Net revenue from TPIAO increased 168.3% to RMB43.1 million (US$5.9

million).

-- Revenue from export sales increased 15.4% to RMB6.8 million (US$0.9

million).

-- Operating income increased 32.9% to RMB48.5 million (US$6.7 million).

-- Net income increased 167.4% to RMB81.5 million (US$11.2 million).

-- Earnings per ADS were RMB3.89 (US$0.53) in 2007, compared to RMB2.13

per ADS in 2006.

Commenting on the results, Dr. Jing Lou, Chief Executive Officer of 3SBio, said, ''2007 was a transformative year for 3SBio, driven by the successful and consistent execution of our strategy. We experienced solid growth across our core product portfolio, and delivered on a number of operational initiatives including continued progress on our development pipeline, the introduction of an oncology-focused sales team, the launch of a new product, and the successful groundbreaking on our new manufacturing facility, among others. From a product perspective, we believe our EPIAO products continued to be the market leader in terms of both revenues and sales volume. Our TPIAO products continued their strong growth, accounting for 23.9% of our total net revenues for the year, up from 12.6% for the fiscal year 2006, demonstrating the robust and rapid market acceptance of this product.''

''Our positive results for the fourth quarter and the full year 2007 are consistent with the financial and operational track record that we have achieved since our incepti
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Class Group of AdvisorsSAN DIEGO, April 20 Trius ... Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, ... seventh members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of ...
... at 100th Annual Meeting of the American Association for ... from Dendreon Corporation (Nasdaq: DNDN ) presented ... Cancer Treatment) or P-11 Phase 3 study suggesting that ... durable and can be maintained following boosting. The results ...
... have discovered a way to use an ancient life form ... in systems that may be surprisingly simple to build compared ... These tiny, single-celled marine life forms have existed for at ... of the life in the oceans, but they also have ...
Cached Biology Technology:Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 3Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 4Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 5Ancient diatoms lead to new technology for solar energy 2
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may be ... be more careful. In the wild, a plant whose seeds ... risk disaster. More than just an insurance policy against late ... dormancy has long-term advantages too: Plants whose seeds put ... more species, finds in a team of researchers working at ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... deafness. , As a leader in stem cell-based research on the ... got a step-by-step plan for making this dream a reality. ... anyone can do it, he's the guy to place your ... this?'" said Heller, PhD, associate professor of otolaryngology, whose accent ...
... all remember a time when we were paralyzed in the ... world, making the right choice can mean the difference between ... choose the thing that leads to a "reward," such as ... and understanding those changes has been the focus of Natural ...
... Your bird field guide may be out of date now ... frogmouth bird on a South Pacific island. , New ... per year is announced globally. David Steadman and Andrew Kratter, ... the surprising new discovery on a collecting expedition in the ...
Cached Biology News:Stem cell transplants explored at Stanford as a possible treatment for hearing loss 2Stem cell transplants explored at Stanford as a possible treatment for hearing loss 3Rewarding fat rats 2UF scientists discover new genus of frogmouth bird in Solomon Islands 2UF scientists discover new genus of frogmouth bird in Solomon Islands 3
... high throughput, water bath thermal cycler capable of ... This equates to 9,216 reactions per run when ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Proliferin (C-14)...
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
Biology Products: